Latest Antibody Stories

Van Andel Research Institute And Dako Sign Agreement To License Cancer Diagnostic Tool

2012-05-16 14:22:12

GRAND RAPIDS, Mich. and GLOSTRUP, Denmark, May 16, 2012 /PRNewswire/ -- Van Andel Research Institute (VARI) and Dako, the Danish-based, worldwide supplier of cancer diagnostic tools today announce an agreement to license, manufacture and distribute cancer diagnostics utilizing the MET4 Antibody. The MET4 Antibody, developed by George F. Vande Woude, Ph.D. and Brian Cao, M.D. of VARI and Beatrice Knudsen, M.D., Ph.D., formerly of the Fred Hutchinson Cancer Research Center, has...

Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway

2012-05-16 10:24:33

BALTIMORE, May 16, 2012 /PRNewswire/ -- In an effort to voice concern on biosimilars pathways for patients with primary immunodeficiency diseases (PIDD), the Immune Deficiency Foundation (IDF) offered oral testimony at last week's U.S. Food and Drug Administration (FDA) public hearing on draft guidance of biosimilars products. IDF urged the FDA to exempt immunoglobulin (Ig) therapies from the biosimilars pathways in order to protect the safety of patients with PIDD. PIDD occurs in...

New Study Shows Adaptive Biotechnologies immunoSEQ Assay Significantly More Sensitive than Traditional Method to Detect Minimal Residual Disease in Leukemia

2012-05-16 10:24:30

SEATTLE, May 16, 2012 /PRNewswire/ -- Adaptive Biotechnologies Corporation, a leading provider of next-generation sequencing assays for the adaptive immune system, announced today results from the first head-to-head comparison of high throughput sequencing (HTS) using immunoSEQ(TM) and traditional flow cytometry. The study, which was conducted in collaboration with Fred Hutchinson Cancer Research Center and the University of Washington Department of Laboratory Medicine, was...

Intellect Neurosciences Expands Its Immunotherapy Pipeline with New Technology Platforms Targeting Pathogenic Protein Aggregates Focused on Huntington's and Parkinson's Diseases

2012-05-16 06:26:53

NEW YORK, May 16, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it has filed three new patent applications with the United States Patent and Trademark Office (USPTO), which expand the Company's immunotherapy pipeline. (Logo:...

5W Public Relations Named PR Agency of Record for IMMUNE Pharmaceuticals

2012-05-15 02:25:59

NEW YORK, May 15, 2012 /PRNewswire/ -- 5W Public Relations, a top 25 U.S. PR Agency today announced the addition of IMMUNE Pharmaceuticals to its roster of corporate clients. IMMUNE Pharmaceuticals is an Israel and U.S. based biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing significant unmet medical needs in the treatment of inflammatory diseases and cancer. 5WPR will execute a comprehensive integrated public relations program...

Scripps Research Institute Scientists Show How Memory B Cells Stay 'In Class' To Fight Different Infections

2012-05-08 09:45:39

Scientists at The Scripps Research Institute have made an important discovery about the internal programming of B cells, the immune cells that make antibodies against infections. The finding opens the way for the development of vaccines that can work more efficiently and hints at therapies for conditions in which B cells cause harm—such as the autoimmune disease lupus erythymatosus, severe allergies, and B-cell lymphomas. The discovery reveals that B cells produce special proteins to...

Sutro Closes $16.5 Million Second Tranche of Series C Financing

2012-05-08 02:28:08

SAN FRANCISCO, May 8, 2012 /PRNewswire/ -- Sutro Biopharma today announced the closing of the $16.5 million second tranche of its Series C financing. This financing was led by Skyline Ventures and included participation of Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners. With the Series C funding, Sutro has raised almost $60 million since its founding in 2003. "We are pleased with the great progress Sutro has made in developing its next generation antibody drug...

Intellect Neurosciences Adds Two New Tau Programs to its Alzheimer's Disease Development Pipeline

2012-05-07 06:26:47

NEW YORK, May 7, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic...

AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences

2012-05-01 02:31:56

SAN DIEGO, May 1, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced an antibody discovery partnership with Gilead Sciences, Inc. to develop novel antibody therapeutics. (Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO) Under this partnership, antibodies generated by AnaptysBio using its proprietary SHM-XEL platform will be transferred to Gilead for worldwide development and commercialization. Gilead has paid an...

Immunosignaturing: An Accurate, Affordable And Stable Diagnostic

2012-04-23 22:30:57

Identifying diseases at an early, presymptomatic stage may offer the best chance for establishing proper treatment and improving patient outcomes. A new technique known as immunosignaturing harnesses the human immune system as an early warning sentry—one acutely sensitive to changes in the body that may be harbingers of illness. Now, Brian Andrew Chase and Barten Legutki, under the guidance of Stephen Albert Johnston, director of the Center for Innovations in Medicine at Arizona State...